Comparative Pharmacology
Head-to-head clinical analysis: E E S versus ERYMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S versus ERYMAX.
E.E.S. vs ERYMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin (E.E.S.) binds to the 50S subunit of bacterial ribosomes, inhibiting peptide chain elongation and protein synthesis. It also exhibits prokinetic effects on the gastrointestinal tract via motilin receptor agonism.
Erythromycin acts by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis. It also acts as a motilin receptor agonist, stimulating gastrointestinal motility.
250-500 mg every 6 hours orally or 15-20 mg/kg/day IV divided every 6 hours.
250-500 mg orally every 6 hours or 500-1000 mg intravenously every 6 hours.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolonged to 4-6 hours in patients with hepatic impairment; may be shorter in children.
Terminal elimination half-life: 1.5–2 hours in adults; prolonged to 4–6 hours in hepatic impairment; requires dosing adjustment in cirrhosis.
Primarily hepatic (biliary) excretion of unchanged drug and active metabolites; approximately 15% of an oral dose is excreted unchanged in urine. The remainder is eliminated via feces as unchanged drug and metabolites.
Renal excretion of unchanged drug: 10–15%; biliary/fecal excretion: 85–90% as active metabolites.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic